Jarno Hoekman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3744386/publications.pdf

Version: 2024-02-01

52	2,330	361296	223716
papers	citations	20 h-index	46 g-index

52	52	52	2532
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The geography of collaborative knowledge production in Europe. Annals of Regional Science, 2009, 43, 721-738.	1.0	395
2	Research collaboration at a distance: Changing spatial patterns of scientific collaboration within Europe. Research Policy, 2010, 39, 662-673.	3.3	395
3	Spatial scientometrics: Towards a cumulative research program. Journal of Informetrics, 2009, 3, 222-232.	1.4	223
4	Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection. Journal of the American Society of Nephrology: JASN, 2015, 26, 2055-2064.	3.0	204
5	Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Reports in VigiBaseÂ®. Drug Safety, 2016, 39, 335-345.	1.4	119
6	Big Pharma, little science?. Technological Forecasting and Social Change, 2014, 81, 22-38.	6.2	105
7	Acquisition of European research funds and its effect on international scientific collaboration. Journal of Economic Geography, 2013, 13, 23-52.	1.6	83
8	Challenges in Advanced Therapy Medicinal Product Development: A Survey among Companies in Europe. Molecular Therapy - Methods and Clinical Development, 2018, 11, 121-130.	1.8	63
9	What drives university research performance? An analysis using the CWTS Leiden Ranking data. Journal of Informetrics, 2017, 11, 859-872.	1.4	60
10	Use of the conditional marketing authorization pathway for oncology medicines in Europe. Clinical Pharmacology and Therapeutics, 2015, 98, 534-541.	2.3	49
11	Characteristics and followâ€up of postmarketing studies of conditionally authorized medicines in the EU. British Journal of Clinical Pharmacology, 2016, 82, 213-226.	1.1	42
12	The Geographical Distribution of Leadership in Globalized Clinical Trials. PLoS ONE, 2012, 7, e45984.	1.1	31
13	Does conditional approval for new oncology drugs in Europe lead to differences in health technology assessment decisions?. Clinical Pharmacology and Therapeutics, 2015, 98, 489-491.	2.3	31
14	Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers. European Journal of Preventive Cardiology, 2016, 23, 758-768.	0.8	29
15	What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings. Cytotherapy, 2020, 22, 388-397.	0.3	29
16	Organizational capacities of national pharmacovigilance centres in Africa: assessment of resource elements associated with successful and unsuccessful pharmacovigilance experiences. Globalization and Health, 2018, 14, 109.	2.4	27
17	Predictors of Congestive Heart Failure after Treatment with an Endothelin Receptor Antagonist. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 490-498.	2.2	24
18	The Importance of Short-Term Off-Target Effects in Estimating the Long-Term Renal and Cardiovascular Protection of Angiotensin Receptor Blockers. Clinical Pharmacology and Therapeutics, 2014, 95, 208-215.	2.3	24

#	Article	IF	Citations
19	EU decision-making for marketing authorization of advanced therapy medicinal products: a case study. Drug Discovery Today, 2018, 23, 1328-1333.	3.2	24
20	The geography of scientific citations. Research Policy, 2019, 48, 1771-1780.	3.3	24
21	A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making. Cytotherapy, 2018, 20, 769-778.	0.3	23
22	Global Regulatory Differences for Geneâ€•and Cellâ€Based Therapies: Consequences and Implications for Patient Access and Therapeutic Innovation. Clinical Pharmacology and Therapeutics, 2018, 103, 120-127.	2.3	22
23	FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines. Frontiers in Pharmacology, 2017, 8, 161.	1.6	21
24	The importance of geographical distance to different types of R&D collaboration in the pharmaceutical industry. Industry and Innovation, 2020, 27, 513-537.	1.7	21
25	A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers. European Journal of Preventive Cardiology, 2014, 21, 434-441.	0.8	19
26	Spatial Scientometrics and Scholarly Impact: A Review of Recent Studies, Tools, and Methods. , 2014, , 127-146.		18
27	Advanced therapy medicinal product manufacturing under the hospital exemption and other exemption pathways in seven European Union countries. Cytotherapy, 2020, 22, 592-600.	0.3	18
28	Accelerating access to new medicines: Current status of facilitated regulatory pathways used by emerging regulatory authorities. Journal of Public Health Policy, 2016, 37, 315-333.	1.0	17
29	CONVERGENCE IN AN ENLARGED EUROPE: THE ROLE OF NETWORK CITIES. Tijdschrift Voor Economische En Sociale Geografie, 2006, 97, 321-326.	1.2	15
30	Changing standards for drug approval: A longitudinal analysis of conditional marketing authorisation in the European Union. Social Science and Medicine, 2019, 222, 76-83.	1.8	14
31	A typology of scientific breakthroughs. Quantitative Science Studies, 2020, 1, 1203-1222.	1.6	13
32	European infrastructure networks and regional innovation in science-based technologies. Economics of Innovation and New Technology, 2011, 20, 517-537.	2.1	12
33	Postauthorization Changes to Specific Obligations of Conditionally Authorized Medicines in the European Union: AÂRetrospective Cohort Study. Clinical Pharmacology and Therapeutics, 2019, 105, 426-435.	2.3	12
34	Estimation of manufacturing development costs of cell-based therapies: a feasibility study. Cytotherapy, 2021, 23, 730-739.	0.3	12
35	The contribution of Ghanaian patients to the reporting of adverse drug reactions: a quantitative and qualitative study. BMC Public Health, 2018, 18, 1384.	1.2	11
36	The Use of Surrogate Endpoints in Regulating Medicines for Cardio-Renal Disease: Opinions of Stakeholders. PLoS ONE, 2014, 9, e108722.	1.1	11

#	Article	IF	Citations
37	Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies. Clinical and Translational Science, 2021, 14, 1566-1577.	1.5	10
38	Factors related to drug approvals: predictors of outcome?. Drug Discovery Today, 2017, 22, 937-946.	3.2	8
39	The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs. International Journal of Health Policy and Management, 2020, , .	0.5	8
40	Key Considerations in the Health Technology Assessment of Advanced Therapy Medicinal Products in Scotland, The Netherlands, and England. Value in Health, 2022, 25, 390-399.	0.1	8
41	An analysis of marketing authorisation applications via the mutual recognition and decentralised procedures in Europe. European Journal of Clinical Pharmacology, 2015, 71, 1237-1244.	0.8	7
42	Regulating advanced therapy medicinal products through the Hospital Exemption: an analysis of regulatory approaches in nine EU countries. Regenerative Medicine, 2020, 15, 2015-2028.	0.8	7
43	Big Pharma, Little Science? A Bibliometric Perspective on Big Pharmaâ€™s R&D Decline. SSRN Electronic Journal, 2012, , .	0.4	5
44	In-Hospital Production of Medicines: Preparing for Disruption. Trends in Biotechnology, 2020, 38, 1045-1047.	4.9	5
45	Development and Regulation of Gene and Cell-Based Therapies in Europe: A Quantification and Reflection. Trends in Pharmacological Sciences, 2020, 41, 67-71.	4.0	5
46	Signals from the Dutch national spontaneous reporting system: Characteristics and regulatory actions. Pharmacoepidemiology and Drug Safety, 2021, 30, 1115-1122.	0.9	5
47	Preâ€approval and postâ€approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: A comparison with standard approved cancer drugs. British Journal of Clinical Pharmacology, 2022, 88, 2169-2179.	1.1	5
48	Four scenarios for the future of medicines and social policy in 2030. Drug Discovery Today, 2022, 27, 2252-2260.	3.2	5
49	Regulatory Safety Learning Driven by the Mechanism of Action: The Case of TNFâ€Î± Inhibitors. Clinical Pharmacology and Therapeutics, 2021, 110, 123-131.	2.3	4
50	Comprehensive evaluation of post-approval regulatory actions during the drug lifecycle â€“ a focus on benefits and risks. Expert Opinion on Drug Safety, 2021, 20, 1-10.	1.0	3
51	Proximity and Stratification in European Scientific Research Collaboration Networks: A Policy Perspective. Advances in Spatial Science, 2013, , 263-277.	0.3	3
52	Publication rates and reported results in a cohort of gene- and cell-based therapy trials. Regenerative Medicine, 2020, 15, 1215-1227.	0.8	2